GlaxoSmithKline PLC ADR
Quarterly Financials
| Values in thousands | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
|---|---|---|---|---|
Revenue | $7,986,000 | $7,516,000 | $8,117,000 | $8,012,000 |
Gross Profit | 5,821,000 | 5,579,000 | 5,558,000 | 5,615,000 |
EBITDA | 3,230,000 | 3,093,000 | 1,119,000 | 1,171,000 |
EBIT | 2,071,000 | 2,270,000 | 707,000 | 220,000 |
Net Income | 1,443,000 | 1,624,000 | 414,000 | -58,000 |
Net Change In Cash | 7,986,000 | 7,516,000 | 8,117,000 | 8,012,000 |
Free Cash Flow | 1,463,000 | 697,000 | 1,194,000 | 1,312,000 |
Cash | 3,599,000 | 4,464,000 | 3,693,000 | 3,192,000 |
Basic Shares | 2,055,000 | 2,070,500 | 2,070,500 | 2,070,500 |
Annual Financials
| Values in thousands | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
Revenue | $31,376,000 | $30,328,000 | $29,324,000 | $34,114,000 |
Gross Profit | 22,328,000 | 21,763,000 | 19,770,000 | 22,511,000 |
EBITDA | 6,668,000 | 9,138,000 | 8,629,000 | 7,756,000 |
EBIT | 4,117,000 | 6,844,000 | 6,482,000 | 5,634,000 |
Net Income | 2,575,000 | 4,928,000 | 4,921,000 | 4,385,000 |
Net Change In Cash | 31,376,000 | 30,328,000 | 29,324,000 | 34,114,000 |
Free Cash Flow | 3,572,000 | 4,424,000 | 5,145,000 | 5,021,000 |
Cash | 3,693,000 | 2,746,000 | 3,723,000 | 4,274,000 |
Basic Shares | 2,071,000 | 2,055,500 | 2,042,000 | 1,620,800 |
Earnings Calls
| Quarter | EPS |
|---|---|
2025-09-30 | $0 |
2025-06-30 | $1.24 |
2025-03-31 | $1.20 |
2024-12-31 | $0.58 |
